IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (External Review Draft)

Notice - This site contains archived material(s)

Archive disclaimer
Archive disclaimer
Archived files are provided for reference purposes only. These files are no longer maintained by the Agency and may be outdated. For current EPA information, go to www.epa.gov. It is EPA's policy to support reasonable accommodation to persons with disabilities, pursuant to the Rehabilitation Act of 1973, 29 U.S.C. 791. If you need assistance with accessing archived files, contact EPA's Reasonable Accommodations or submit a request using the Contact Us form.


Abstract

The IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) was released for external peer review in September 2016. The EPA’s Science Advisory Board’s (SAB) Chemical Assessment Advisory Committee (CAAC) will conduct a peer review of the scientific basis supporting the RDX assessment and release a final report of their review. Information regarding the peer review can be found on the SAB website.

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX, or Royal Demolition eXplosive) is a military explosive with limited civilian uses. In the United States, RDX is produced at Army ammunition plants; it is not produced commercially.

An oral reference dose (RfD) and an oral cancer slope factor are currently available on IRIS. A reassessment of the human health effects of RDX, including both cancer effects and effects other than cancer, is being undertaken.

Impact/Purpose

EPA is undertaking an update of the Integrated Risk Information System (IRIS) health assessment for RDX. The outcome of this project is an updated Toxicological Review and IRIS Summary for RDX that will be entered into the IRIS database.

Status

Following external peer review, the assessment will be revised taking into consideration peer review comments. The assessment will then undergo a final EPA internal review and a review by other federal agencies and the Executive Office of the President. Once final, the assessment will be posted to the IRIS database.

Citation

U.S. EPA. IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (External Review Draft). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-16/208, 2016.

History/Chronology

Date Description
01-Aug 2013EPA released preliminary draft materials for discussion at the December IRIS Bimonthly Public Meeting.
02-Dec 2013EPA discussed preliminary draft materials at the December 12-13, 2013 IRIS Bimonthly Public Meeting. Presentations are also available on the meeting web site.
03-Mar 2016EPA released the public comment draft for a 60-day review period and announced it will be discussed at the May 10, 2016 IRIS Public Science Meeting. EPA also released the interagency science consultation documents, comments from reviewers, and EPA's response to major comments. [Federal Register Notice: Mar 10, 2016]
04-Mar 2016EPA announced a request for nominations of experts to augment the SAB CAAC for the review of the draft RDX assessment. Any related questions should be directed to the SAB. [SAB Federal Register Notice Mar 18, 2016]
05-May 2016EPA discussed the draft RDX Toxicological Review at the May IRIS Public Science Meeting.
06-Sep 2016EPA released the external review draft for peer review by EPA's Science Advisory Board (SAB) Chemical Assessment Advisory Committee (CAAC). Any related questions should be directed to the SAB. [SAB Federal Register Notice Sep 29, 2016]
07-Dec 2016EPA's Science Advisory Board (SAB) Chemical Assessment Advisory Committee (CAAC) convened a 3-day meeting to conduct a peer review of the draft Toxicological Review.
08-Apr 2017EPA's Science Advisory Board (SAB) held a 2-day public external peer review teleconference to discuss the draft Toxicological Review. [Federal Register Notice Mar 22, 2017]

Docket

Comments on the assessment may be submitted and reviewed using the Docket ID EPA-HQ-ORD-2013-0430